Wells Fargo Initiates Coverage On Hamilton Lane with Overweight Rating, Announces Price Target of $103
Wells Fargo analyst Daniel Welden initiates coverage on Hamilton Lane (NASDAQ:HLNE) with a Overweight rating and announces Price Target of $103.
Stocks · News reference
Alpha Buying: When a CEO Spends $5 Million on His Own Stock, Pay Attention
Corporate executives say optimistic things about their companies every day. They appear on earnings calls, investor presentations and financial television programs to explain why the latest disappointing quarter is
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Oppenheimer Maintains Outperform on Hamilton Lane, Lowers Price Target to $181
Amazon, Alphabet, Tesla Stock Rises: Robinhood Traders Sell Anyway
Amazon, Alphabet and Tesla rose Friday, but Robinhood traders sold all three. The monthly data suggests profit-taking, not an AI trade exit.
Summit Therapeutics Announces Closing Of AstraZeneca's $2B Convertible Preferred Investment, Equivalent To $18.36/Share Of Common Stock
AstraZeneca, Daiichi Sankyo Expand Cancer Push Through Summit Partnership
AstraZeneca & Daiichi Sankyo team up with Summit Therapeutics to test Datroway + ivonescimab combo in triple-negative breast cancer.
Summit Therapeutics, AstraZeneca And Daiichi Sankyo Announce Clinical Trial Collaboration To Evaluate Ivonescimab With TROP2-Directed ADC Datroway Across Multiple Tumor Types, Starting With Phase III First-Line Triple-Negative Breast Cancer Study
Collaboration Intends to Evaluate Ivonescimab in Combination with Datroway across Multiple Tumor Types Starting with a Phase III Study in First-Line Triple Negative Breast Cancer